In the fast-paced world of healthcare technology, Base Genomics emerges as a groundbreaking epigenetics company, revolutionizing the field of cancer detection. With their innovative blood test for early-stage cancer and minimal residual disease, Base Genomics is at the forefront of the fight against cancer. Powered by their proprietary TAPS (TET-assisted pyridine borane sequencing) technology, the company is changing the game by providing accurate and cost-effective solutions that combine epigenetic and genetic analysis.
Unleashing the Power of TAPS Technology:
At the heart of Base Genomics’ success lies their pioneering TAPS technology. Developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford, TAPS is a groundbreaking chemical reaction that converts methylated cytosine to thymine under mild conditions. Unlike traditional bisulfite sequencing methods, TAPS preserves DNA integrity, ensuring more DNA is available for sequencing. This innovation not only reduces sequencing costs but also enables simultaneous analysis of both epigenetic and genetic information.
Redefining Early-stage Cancer Diagnosis:
Base Genomics is committed to revolutionizing cancer diagnosis by providing a non-invasive blood test that detects early-stage cancer and minimal residual disease. By leveraging the power of epigenetics, their test offers unprecedented sensitivity and accuracy. TAPS technology allows the detection of DNA methylation patterns that can indicate the presence of cancerous cells, even before conventional symptoms emerge. This early detection potential has the potential to save countless lives by enabling timely intervention and treatment.
Advancing Precision Medicine:
With precision medicine on the rise, Base Genomics plays a crucial role in tailoring cancer treatments to individual patients. By combining epigenetic and genetic analysis, their comprehensive approach provides a deeper understanding of each patient’s unique cancer profile. This information allows oncologists to develop personalized treatment plans, ensuring that therapies are targeted and effective. The integration of TAPS technology with precision medicine opens up new possibilities for improving patient outcomes and accelerating progress in the fight against cancer.
Conclusion:
Base Genomics, based in Oxford, Oxfordshire, United Kingdom, is a trailblazing epigenetics company dedicated to transforming cancer detection through their innovative TAPS technology. By harnessing the power of epigenetics and genetic analysis, they are paving the way for early-stage cancer diagnosis and precise treatment strategies. With their commitment to improving patient outcomes, Base Genomics is reshaping the future of cancer care and bringing hope to millions worldwide.
Website: https://www.basegenomics.com/
Twitter: https://twitter.com/BaseGenomics
Facebook: https://www.facebook.com/pg/Base-Genomics-104187144609476
